Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;20(8):2387-2389.
doi: 10.1111/jocd.14304. Epub 2021 Jun 27.

Acute generalized exanthematous pustulosis following treatment with favipiravir in a patient with COVID-19 without hydroxychloroquine use: Report of the first case

Mehmet Fatih Atak  1 , Banu Farabi  2 , Atiye Akbayrak  3 , Mehmet Berati Kalelioğlu  4 , Babar K Rao  2
Affiliations

Acute generalized exanthematous pustulosis following treatment with favipiravir in a patient with COVID-19 without hydroxychloroquine use: Report of the first case

Mehmet Fatih Atak et al. J Cosmet Dermatol. 2021 Aug.
No abstract available

Keywords: AGEP; COVID-19; acute generalized exanthematous pustulosis; cutaneous adverse event; favipiravir.

PubMed Disclaimer

Conflict of interest statement

Dr. Babar K. Rao is a consultant for Caliber ID (The manufacturer of VivaScope). The other authors have no conflict of interest to declare.

Figures

FIGURE 1
FIGURE 1
Clinical images of the patient at the time of presentation. (A) Diffuse erythematous, edematous plaques involving the trunks and proximal extremities. (B) Annular, erythematous plaques with polycyclic contours and superficial pustule lakes on the forearm. (C) Close image of the abdominal lesions showing polycyclic plaques and grouped pustular lesions along the borders of the lesion. (D) Widespread desquamation of the skin after the treatment on day 8
FIGURE 2
FIGURE 2
Histopathologic images of the skin biopsy obtained from the abdominal lesion, where the pustules were present. (A) Acanthosis of the epidermis with numerous neutrophilic subcorneal/intracorneal spongiotic pustules with papillary dermal edema. Mixed inflammatory infiltrate composed of lymphocytes, neutrophils, and rare eosinophils in the dermis (H&E ×10). (B) Higher magnification of the dermo‐epidermal junction shows abundant eosinophilic infiltrate in the papillary dermis (H&E ×20).
See this image and copyright information in PMC

References

    1. Agrawal U, Raju R, Udwadia ZF. Favipiravir: a new and emerging antiviral option in COVID‐19. Med J Armed Forces India. 2020;76(4):370‐376. - PMC - PubMed
    1. Haraszti S, Sendil S, Jensen N. Delayed presentation of acute generalized Exanthematous pustulosis following treatment with Cefepime in a patient with COVID‐19 without the use of hydroxychloroquine. Am J Case Rep. 2020;21:e926901. - PMC - PubMed
    1. Stingeni L, Francisci D, Bianchi L, et al. Severe adverse drug reaction in SARS‐CoV‐2 infection: AGEP induced by ceftriaxone and confirmed by patch test. Contact Dermatitis. 2021. 10.1111/cod.13857. Epub ahead of print. - DOI - PMC - PubMed
    1. Erdem HA, Korkmaz Ekren P, ÇaĞlayan D, et al. Treatment of SARS‐cov‐2 pneumonia with favipiravir: Early results from the Ege University cohort. Turk J Med Sci. 2020. 10.3906/sag-2008-33 - DOI - PMC - PubMed
    1. Farabi B, Atak MF. Isolated maculopapular eruption localized to head and neck: A cutaneous sign of COVID‐19 infection. Dermatol Ther. 2020:e14468. - PubMed